Scholfield DP - Search Results

1

Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer.

Murray A, Simms MS, Scholfield DP, Vincent RM, Denton G, Bishop MC, Price MR, Perkins AC. Murray A, et al. Among authors: scholfield dp. J Nucl Med. 2001 May;42(5):726-32. J Nucl Med. 2001. PMID: 11337567 Free article.

2

Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer.

Simms MS, Murray A, Denton G, Scholfield DP, Price MR, Perkins AC, Bishop MC. Simms MS, et al. Among authors: scholfield dp. Urol Res. 2001 Feb;29(1):13-9. doi: 10.1007/s002400000147. Urol Res. 2001. PMID: 11310209 Clinical Trial.

3

99mTechnetium-C595 radioimmunoscintigraphy: a potential staging tool for bladder cancer.

Simms MS, Perkins AC, Price MR, Scholfield DP, Bishop MC. Simms MS, et al. Among authors: scholfield dp. BJU Int. 2001 Nov;88(7):686-91. doi: 10.1046/j.1464-410x.2001.02348.x. BJU Int. 2001. PMID: 11890238

4

MUC1 mucin in urological malignancy.

Scholfield DP, Simms MS, Bishop MC. Scholfield DP, et al. BJU Int. 2003 Apr;91(6):560-6. doi: 10.1046/j.1464-410x.2003.04132.x. BJU Int. 2003. PMID: 12656915 Review. No abstract available.

5

Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer.

Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE, Bishop MC. Simms MS, et al. Among authors: scholfield dp. Br J Cancer. 2000 Aug;83(4):443-6. doi: 10.1054/bjoc.2000.1315. Br J Cancer. 2000. PMID: 10945488 Free PMC article. Clinical Trial.

6

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.

Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E. Chapple C, et al. BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1. BJU Int. 2014. PMID: 24552358 Clinical Trial.

7

Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.

Chapple C, Oelke M, Kaplan SA, Scholfield D, Arumi D, Wagg AS. Chapple C, et al. Curr Med Res Opin. 2015 Jun;31(6):1201-43. doi: 10.1185/03007995.2015.1032917. Epub 2015 Apr 23. Curr Med Res Opin. 2015. PMID: 25798911 Review.

8

Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry.

Klarskov N, Darekar A, Scholfield D, Whelan L, Lose G. Klarskov N, et al. Int Urogynecol J. 2014 Jun;25(6):755-60. doi: 10.1007/s00192-013-2269-6. Epub 2013 Nov 21. Int Urogynecol J. 2014. PMID: 24258099 Clinical Trial.

9

Development of a predictive model for urgency urinary incontinence.

Darekar A, Carlsson M, Quinn S, Ntanios F, Mangan E, Arumi D, Scholfield D. Darekar A, et al. Contemp Clin Trials. 2016 Nov;51:44-49. doi: 10.1016/j.cct.2016.09.005. Epub 2016 Sep 27. Contemp Clin Trials. 2016. PMID: 27687744

10

Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials.

Wyndaele JJ, Schneider T, MacDiarmid S, Scholfield D, Arumi D. Wyndaele JJ, et al. Int J Clin Pract. 2014 Jul;68(7):830-40. doi: 10.1111/ijcp.12425. Epub 2014 Apr 22. Int J Clin Pract. 2014. PMID: 24754814 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters